Health Care Archives | Page 136 of 137 | Smartkarma

Teladoc Health, Inc. (TDOC US), the whole-person virtual care industry leader in scale, clinical breadth, and outcomes, reported 70% revenue CAGR over the last three years.
The company expects 25% annual expansion in revenue per member, which together with 1–5% per year growth in membership will lead to 25–30% revenue CAGR during 2021–2024.
Teladoc has a strong growth opportunity amid a large TAM of 298 million total insured lives in the U.S., of which the company has penetrated just 30%.

Aier Eye Hospital Group (300015.CH) – More than Just Bribery Scandal

According to public news, the recent bribery scandal of Aier Eye Hospital Group (300015 CH) has raised widespread concern. Shenzhen stock Exchange also issued a letter of inquiry.
The development model based on M&A funds helps rapid expansion, but also leads to profit orientation and large goodwill balance, indicating potential risks.
The biggest risk is the revolutionary technology/drugs to disrupt the business value of Aier’s medical services. So, Aier could be a short-term trade, but not a long-term hold.

Before it’s here, it’s on Smartkarma

Jan 19

Health Care: Dong E E Jiaoco Ltd A and more

By Smartkarma Daily Briefs | Daily Briefs, Healthcare

In today’s briefing:

Dong E E Jiao (000423.CH) – Could the New Chairman Turn Things Around?

Dong E E Jiao (000423.CH) – Could the New Chairman Turn Things Around?

The high price of EJiao discouraged consumers, leading to increasing inventory backlog in the distribution channel and reduction in payment collection, which finally resulted in Dong-E-E-Jiao’s net loss in 2019.
Although the performance has showed a recovery trend since 2020,concerns on raw material shortage, low inventory turnover, single product structure, high selling expense ratio and fierce market competition still remain.
There is still a long way to go for the Company to get back to peak, so we are conservative about Dong E E Jiaoco Ltd A (000423 CH)’s outlook.

Before it’s here, it’s on Smartkarma

Jan 18

Health Care: Paramount Bed Holdings Co Lt, Shenzhen Chipscreen Biosciences-A and more

By Smartkarma Daily Briefs | Daily Briefs, Healthcare

In today’s briefing:

Paramount Bed (7817 JP): Poised to Grow on the Back of Recovery from the COVID-19
Shenzhen Chipscreen Biosciences (688321.CH) – Risks Outweigh Opportunities

Paramount Bed (7817 JP): Poised to Grow on the Back of Recovery from the COVID-19

Paramount Bed Holdings Co Lt (7817 JP) reported record-high sales and profit during six-month ended on September 30, 2021, driven by strong domestic demand due to recovery from the pandemic.
Each of businesses are receiving steady inquiries from market and is expected to perform strongly. Management raised full-year guidance after a strong Q1 results.
New products are driving margin for the company. Nemuri SCAN continues to perform well as remote monitoring using sensor technology is receiving more attention amid the COVID-19 pandemic.

Shenzhen Chipscreen Biosciences (688321.CH) – Risks Outweigh Opportunities

The small market space of peripheral T-cell lymphoma indication and the fierce market competition of other indications, products and candidates make the Company’s future commercialization performance uncertain.
The continuous large investment in R&D, high selling expenses, and declining R&D expending capitalization would further drag down profitability.
So, our view is that we are conservative about Chipscreen Biosciences’s outlook at the current stage.

Before it’s here, it’s on Smartkarma

Jan 16

Health Care: Green Cross and more

By Smartkarma Daily Briefs | Daily Briefs, Healthcare

In today’s briefing:

Green Cross (006280 KS): Look Ahead for Key Milestones Amid Covid Vaccine Related Setback

Green Cross (006280 KS): Look Ahead for Key Milestones Amid Covid Vaccine Related Setback

Green Cross (006280 KS) is currently waiting for marketing approval from the FDA for its immune globulin intravenous injection, which will mark its entry into the U.S. market.
The company will start commercializing its hemophilia A treatment, GreenGene F in China market this year. As a third-generation product, GreenGene is expected to gain substantial market share.
Green Cross shares remained subdued last year, as the company could not finalize a contract manufacturing deal for COVID-19 vaccine.

Before it’s here, it’s on Smartkarma

Jan 14

Health Care: Mani Inc, Hangzhou Bioer Technology and more

By Smartkarma Daily Briefs | Daily Briefs, Healthcare

In today’s briefing:

Mani Inc (7730 JP): No Immediate Respite Seen
Bioer IPO: Currently Holding Strong but Would Growth Rates Sustain Post-COVID?

Mani Inc (7730 JP): No Immediate Respite Seen

By Shifara Samsudeen, ACMA, CGMA

Mani Inc (7730 JP) offers medical devices, which are mainly used in the elective procedures including cataract surgery and dental procedures.
In FY21, the company missed its guidance for both revenue and operating income by 2% and 5%, respectively, due to higher-than-expected impact of the COVID-19.
With the rising cases of highly infectious Omicron variant of the COVID-19 in major operating regions, the company is expected to miss or lower its FY22 guidance.

Bioer IPO: Currently Holding Strong but Would Growth Rates Sustain Post-COVID?

Bioer designs, manufactures and sells three categories of PCR products: instruments, reagents and consumables. With the spread of COVID-19, the company experienced strong growth in revenue and margin improvements.
The company has filed for an IPO to list its shares on the Hong Kong Stock Exchange and plans to raise proceeds of around US$200m
Strong growth in Bioer’s revenue over the last two years was predominantly driven by the spread of COVID-19. We are concerned on the company’s ability to maintain its revenues post-COVID.

Before it’s here, it’s on Smartkarma

Jan 12

Health Care: Paradigm Biopharmaceuticals, Ipca Laboratories, Beijing Chunlizhengda Medical Instruments, Abbott India and more

By Smartkarma Daily Briefs | Daily Briefs, Healthcare

In today’s briefing:

Paradigm Biopharmaceuticals (PAR AU): Concerns on First Potentially Commercialized Product
Ipca Laboratories: Two for One Share Stock Split
Chunlizhengda Medical Instruments (1858.HK) – Conservative About the Outlook
Pick of the Week: Abbott India Ltd

Paradigm Biopharmaceuticals (PAR AU): Concerns on First Potentially Commercialized Product

Paradigm Biopharmaceuticals (PAR AU) is re-pioneering patent expired, existing drug molecule pentosan polysulfate sodium as a potential treatment of osteoarthritis, under the brand name Zilosul.
With a current addressable patient population of 72 million people, Zilosul has an annual revenue potential of more than $10 billion, if approved.
Inherent safety concern on the existing FDA-approved indication and Paradigm’s financial capability are the near-term overhangs on the commercialization prospect of the drug.

Ipca Laboratories: Two for One Share Stock Split

By ICICI Securities Limited

The Ipca Laboratories stock has been sub-divided from one existing equity share of Rs 2 each face value into two equity shares of Rs 1 each face value
Consequently, Ipca Lab’s share price has dropped to ~Rs 1099/share from ~Rs 2200/share.
Hence, our target price has also now been revised to Rs 1245/share post this corporate action.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Chunlizhengda Medical Instruments (1858.HK) – Conservative About the Outlook

Last year end, Beijing Chunlizhengda Medical Instruments (1858 HK) was listed on the SSE STAR Market, but fell on debut.
The major concerns include performance slowdown, loss of bidding in centralized procurement, problematic sales model, poor gross profit margin, single products risk and weak innovation capability and international business.
Our view is that there is no immediate prospect of significant improvement. With too many uncertainties and concerns, we are conservative about Chunlizhengda’s outlook despite the large A/H premium.

Pick of the Week: Abbott India Ltd

By Axis Direct

Revenue growth of Abbott India Ltd (AIL) for FY21 has outpaced the Indian Pharma Market (IPM) growth by 100 bps majorily contributed by addition of new products
AIL has leadership position in 9 top brands out of 10 in their respective therapies
We recommend BUY with a TP of Rs 20,000/share.

Before it’s here, it’s on Smartkarma

By Shifara Samsudeen, ACMA, CGMA

Jan 11

Health Care: Australian Pharmaceutical Industries, Gaush Meditech, Takeda Pharmaceutical, Bloomage Biotechnology Corporation-A and more

By Smartkarma Daily Briefs | Daily Briefs, Healthcare

In today’s briefing:

Aussie Pharma: Path Cleared For Wesfarmers As Woolies Walks.
Gaush Meditech (高视医疗科技) Pre-IPO: Need a Very Convincing Story
Takeda: Excessive Reaction to Recent Setback in Trials; Drop in Share Price Offer Attractive Entry
Bloomage Biotechnology (688363.CH) Vs Imeik Technology (300896.CH) – The Logic and the Outlook

Aussie Pharma: Path Cleared For Wesfarmers As Woolies Walks.

By David Blennerhassett

Woolworths Ltd (WOW AU)‘s surprise takeover Offer for Australian Pharmaceutical Industries (API AU) last month is surpassed by its surprise decision to walk away.
This leaves Wesfarmers Ltd (WES AU) in the driving seat – provided the ACCC is satisfied competition is not impeded.
The cash consideration of $1.55 under Wesfarmers’ Offer will be reduced by any permitted dividend. A final fully franked dividend of A$0.02/share has been paid.

Gaush Meditech (高视医疗科技) Pre-IPO: Need a Very Convincing Story

By Ke Yan, CFA, FRM

Gaush Meditech is a leading distributor of ophthalmic medical device in China. The company is looking to raise up to USD 200m via a Hong Kong listing.
We look at the company’s key segments and products. The company’s story of being a comprehensive distributor and R&D does not impress us.
The company is mainly held by the founder’s family. We think the company should be valued as a distributor and not innovative medical device company.

Takeda: Excessive Reaction to Recent Setback in Trials; Drop in Share Price Offer Attractive Entry

Takeda is currently trading at JPY3,175 per share, slightly above its all-time low of JPY3,105 per share. Shares are currently at a 27% discount to its peak in March 2021.
The company has been divesting its non-core assets and reorganising its business around five core areas: GI, Rare Diseases, Plasma-Derived Therapies, Oncology, Neurosciences and Others.
Takeda’s share price started plunging after the suspension of a phase 2 study of TAK-994 in October 2021 following the emergence of a safety signal.

Bloomage Biotechnology (688363.CH) Vs Imeik Technology (300896.CH) – The Logic and the Outlook

There’re many uncertainties about Imeik’s development strategy, resilience in front of risks and corresponding business performance, which could make it difficult for the market to calmly view the next fluctuation.
Despite lower profit margin, Bloomage is more R&D oriented and characterized by integration of industrial chain,enabling it to establish wider moat and move forward more stably in the long term.
Our view is that Bloomage Biotechnology Corporation-A (688363 CH) is expected to have more potential and imagination space than Imeik Technology Development (300896 CH) in the future.

Before it’s here, it’s on Smartkarma

Jan 10

Health Care: Shanghai Junshi Bioscience and more

By Smartkarma Daily Briefs | Daily Briefs, Healthcare

In today’s briefing:

Shanghai Junshi Bioscience (1877.HK/688180.CH) – Behind the “break Up” with AstraZeneca

Shanghai Junshi Bioscience (1877.HK/688180.CH) – Behind the “break Up” with AstraZeneca

Shanghai Junshi Bioscience Co. Ltd. (1877 HK) announced that it has terminated its PD-1 commercialization partnership with AstraZeneca. Lower-than-expected sales performance is seen as the key reason.
Junshi’s commercialization team is the weakest among the domestic Top Four.As the FDA’s attitude may have changed, the logic of exporting innovative domestic drugs to foreign markets could be shaken.
Given the poor financing environment,it’s challenging for Junshi to afford large investment in R&D and licensing deals by just relying on cash in hand and cashflow generating from commercialized products.

Before it’s here, it’s on Smartkarma

Jan 09

Health Care: Telix Pharmaceuticals and more

By Smartkarma Daily Briefs | Daily Briefs, Healthcare

In today’s briefing:

Telix Pharmaceuticals (TLX AU): Stepping Ahead with First Product Approved in the U.S.

Telix Pharmaceuticals (TLX AU): Stepping Ahead with First Product Approved in the U.S.

Last month, Telix Pharmaceuticals (TLX AU) received FDA approval for its first cancer imaging product, Illuccix. Commercial launch of Illuccix will be the major milestone for the company in 2022.
EU approval for Illucix is expected in March. Illuccix has multi-billion-dollar global market opportunity, driven by rising incidence of prostate cancer, increasing clinical adoption, and geography expansion.
The company has a rich pipeline targeting seven indications, having high unmet medical needs. Telix is expected to file for kidney cancer imaging product, TLX250-CDx in early 2022.

Before it’s here, it’s on Smartkarma

Jan 08

Health Care: Osstem Implant and more

By Smartkarma Daily Briefs | Daily Briefs, Healthcare

In today’s briefing:

Osstem Implant – Where to Next?

Osstem Implant – Where to Next?

By Ken S. Kim

The family of the accused has said that the embezzlement was not an act of one man but due to orders taken from superiors.
The recovery shoudn’t be an issue as the accused had bought in gold in Dec and Dongjin Chem has not had a substantial drop for the period in question.
When did this start? According to the Capital Market Act, if an investor incurs loss due to false statements/omissions in the business/quarterly report, the company is responsible for damages.

Before it’s here, it’s on Smartkarma